Search Results
May 18, 2026, 04:47 ET Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease
Congenital adrenal hyperplasia (CAH) and Cushing's disease (CD) are rare disorders characterized by excess adrenocorticotropic hormone (ACTH) produced in the brain1,2Current treatments are limited by suboptimal disease control and treatment-related complications3,4Asedebart
More news about: H. Lundbeck A/S
May 17, 2026, 21:13 ET El Día de la Innovación de ACROBiosystems llega a Zúrich
inmunitaria y plataforma modular", presentó datos de 36 pacientes con leucemia linfoblástica aguda de células B (B-ALL) tratados con células CAR-T anti-CD19 modificadas genéticamente con Sleeping Beauty, logrando una tasa de remisión completa del 83% con persistencia a largo plazo. Asimismo, destacó cómo
More news about: ACROBiosystems Group
May 17, 2026, 21:12 ET ACROBiosystems Innovation Day in Zürich bringt führende Köpfe zur Erkundung neuer Biotech-Grenzen zusammen
Non-viral Engineering, Immune Evasion, and Modular Platform" präsentierte sie Daten von 36 B-ALL-Patienten, die mit Sleeping Beauty-entwickelten Anti-CD19-CAR-T-Zellen behandelt wurden und 83 % vollständige Remissionen mit Langzeitpersistenz erreichten. Sie hob auch hervor, wie Multi-Omics-Analysen die
More news about: ACROBiosystems Group
May 17, 2026, 21:10 ET Zurich accueille la journée de l'innovation d'ACROBiosystems : les plus grands esprits s'unissent pour explorer les frontières de la biotechnologie
virale, évasion immunitaire et plateforme modulaire), elle a présenté les données de 36 patients atteints de LAL-B traités avec des cellules CAR-T anti-CD19 issues de l'ingénierie Sleeping Beauty, qui ont obtenu un taux de rémission complète de 83 % avec une persistance à long terme. Elle a également souligné
More news about: ACROBiosystems Group
May 15, 2026, 16:30 ET Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies;LYMPHIR administered prior to commercial CD19-directed CAR-T therapy in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with positive topline safety and efficacy
More news about: Citius Pharmaceuticals, Inc.
May 15, 2026, 10:13 ET A2Z Provides Update to Financial Results for First Quarter 2026
https://viavid.webcasts.com/starthere.jsp?ei=1762627&tp_key=3b4649d7cd.About A2Z Cust2Mate Solutions Corp.A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) makes in-store
More news about: A2Z Cust2Mate Solutions Corp.
May 15, 2026, 06:00 ET A2Z Announces Financial Results for First Quarter 2026
https://viavid.webcasts.com/starthere.jsp?ei=1762627&tp_key=3b4649d7cd.About A2Z Smart Technologies Corp.A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) makes in-store
More news about: A2Z Cust2Mate Solutions Corp.
May 15, 2026, 03:43 ET Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026
(EHA) Congress. The abstract is now available on the EHA Congress platform. Ligufalimab is Akeso's proprietary next-generation humanized IgG4 anti-CD47 monoclonal antibody. The study evaluated ligufalimab in combination with azacitidine (AZA) and venetoclax (VEN) in patients with treatment-naïve acute
More news about: Akeso, Inc.
May 14, 2026, 10:34 ET ATRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen." Atara said that "[t]he CRL indicates that the FDA is unable to approve the EBVALLO™ BLA in its present form" because, according
More news about: Faruqi & Faruqi, LLP
May 14, 2026, 08:10 ET CREATE Medicines Strengthens Clinical and Scientific Advisory Board with Appointment of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD
Appointments come as CREATE advances CRT-402, its lead in vivo CD19 CAR-T program, to clinical development for B cell-driven autoimmune diseaseCAMBRIDGE, Mass., May 14, 2026 /PRNewswire/
More news about: CREATE Medicines, Inc.
May 14, 2026, 08:00 ET CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology
Financing to support advancement of CREATE's repeat dose capable CD19 targeted in vivo CAR-T therapy for autoimmune disease into the clinic, expansion of its dual CAR CD19 x BCMA program, and continued progress across the oncology portfolioRound co-led by existing
More news about: CREATE Medicines, Inc.
May 14, 2026, 08:00 ET DEEPX and Ultralytics Forge Strategic Alliance to Define the Global Standard for Physical AI in the YOLO Community
software development and hardware execution.A Future-Proof AI Foundation: To ensure DEEPX remains the industry benchmark, a dedicated CI/CD pipeline guarantees continuous, out-of-the-box compatibility with every new Ultralytics update and AI model evolution.Accelerating Global
More news about: DEEPX
May 14, 2026, 07:30 ET Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
all-oral combination of selinexor 40 mg, pomalidomide and dexamethasone (SPd40) in patients with previously treated multiple myeloma who received an anti-CD38 as their immediate prior line of therapy.Anticipated Catalysts and Operational ObjectivesMyelofibrosis Present
More news about: Karyopharm Therapeutics Inc.
May 14, 2026, 03:00 ET DEEPX and Ultralytics Forge Strategic Alliance to Define the Global Standard for Physical AI
quantization and validation bridge the gap between software development and hardware execution. Continuous Compatibility: A dedicated CI/CD pipeline ensures out-of-the-box support with every new Ultralytics update and AI model evolution. Global Community Enablement: Joint
More news about: DEEPX
May 12, 2026, 14:35 ET CD Valet Shares Data Verification Policy for Certificate of Deposit Rates
here.About CD ValetCD Valet is a CD marketplace that features verified CD rates from federally insured banks and credit unions. With tens of thousands of CD offers tracked across the country, CD Valet gives savers a clear view of top rates and helps them explore high-yield CD options with
More news about: CD Valet
May 12, 2026, 11:46 ET First-in-human trial demonstrates promise of implantable cytokine factories for ovarian cancer
activity that supports continued development."Immune analyses revealed that the therapy successfully activated key antitumor immune cells, including CD8+ T cells and natural killer cells, without expanding regulatory T cells that can suppress immune responses, a known limitation of conventional IL-2
More news about: Rice University
May 12, 2026, 10:00 ET QuerySurge is Now Available in the AWS Cloud with Pay-As-You-Go Pricing
and ETL/ELT pipelines, as well as Snowflake, Databricks, and 200+ other data technologies.Seamless CI/CD and DataOps Integration: Integrate data validation directly into CI/CD and DataOps release workflows for continuous data quality assurance.AI-Accelerated Test Creation: QuerySurge
More news about: QuerySurge
May 12, 2026, 10:00 ET Exploited vulnerabilities jump 43% in Q1 as cyber criminals leverage AI for more effective attacks - Beazley Security
threat actor group TeamPCP, which used an automated AI agent, dubbed hackerbot-claw, to identify and exploit misconfigurations in GitHub CI/CD workflows. The attackers ultimately poisoned a well-known security scanner, Trivy, with credential-stealing malware, cascading compromise risk across
More news about: Beazley Security
May 12, 2026, 09:00 ET Endor Labs Expands AURI from Securing Code to Securing Agents that Produce Code
and blocks malicious or vulnerable packages before they reach the environment. This is all accomplished without disrupting developer workflows or CI/CD pipelines. Key features include:Real-time scanning of every open-source package across npm, PyPI, NuGet, Maven, and other major
More news about: Endor Labs
May 12, 2026, 03:04 ET ACROBiosystems Innovation Day Lands in Zurich: Top Minds Unite to Explore Biotech Frontiers
Non-viral Engineering, Immune Evasion, and Modular Platform", she presented data from 36 B-ALL patients treated with Sleeping Beauty-engineered anti-CD19 CAR T cells, achieving an 83% complete remission rate with long-term persistence. She also highlighted how multi-omic analyses identified tumor microenvironment
More news about: ACROBiosystems Group
May 12, 2026, 01:30 ET Kaneka Ubiquinol™與Eqology合作榮獲2026年備受矚目的Vitafoods Europe創新獎
[i]Eqology/Pharma Marine.分析報告：Pure Arctic Oil Heart & Energy的氧化穩定性指數。基於Rancimat法和AOCS Cd 12b-92方法的內部方法AM29。2025年10月。Kaneka Corporation。Kaneka
More news about: Kaneka Ubiquinol™
May 11, 2026, 09:00 ET Hint Reframes Hydration as Desire, Not Discipline, With 'MMMMM Water™' Campaign
Operations, Katie Scott Creative Agency: MythologyECD / Partner, Audrey AttalECD / Partner, Kim HaxtonCD, Jake O'Donnell CD, Brad KranjecArt Director, Jeanette Tran Head of Studio & Production Manager, Manuel AbreuManaging Director,
More news about: Hint Water
May 11, 2026, 08:14 ET Myrtelle to Present Clinical Data and Regulatory Progress for MYR-101 Gene Therapy Program at ASGCT 2026
initial manifestations of CD. As the disease progresses, seizures, spasticity, difficulties in swallowing, and overall muscle deterioration emerge with most affected children developing life-threatening complications by approximately 10 years of age. Currently, there are no cures for CD, and only palliative
More news about: Myrtelle, Inc
May 11, 2026, 08:00 ET Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
complete radiographic response.Up to 15-fold mean increase in systemic T-Cell expansion: Peripheral blood analysis showed robust CD8+ and CD4+ T-cell proliferation in combination-treated patients, providing mechanistic support for the observed clinical activity.Manageable safety
More news about: Inhibrx Biosciences, Inc.
May 11, 2026, 08:00 ET Testaify Expands Autonomous Testing Platform for the AI Development Era
future runs can focus more effectively on new or changed behavior.Additional enhancements include:API integration for CI/CD workflowsConfigurable release thresholds and blocking logicExpanded findings management and replay capabilitiesHuman-readable
More news about: Testaify, Inc.